ISCHEMIX

Ischemix, Inc., a pharmaceutical company, develops small molecule drugs for the treatment and prevention of ischemia-reperfusion injury. Its product includes CMX-2043, a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule, as well as is used for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention procedures. The company’s drugs also protect against the damaging effects associated with ischemia in brain and other organs. Ischemix, Inc. was formerly known as CereMedix, Inc. and changed its name to Ischemix, Inc. in February 2006. The company was founded in 1999 and is headquartered in Maynard, Massachusetts.